Table 2 Sensitivity and specificity percentages and costs of imaging tests based on location of the metastatic breast cancer

From: The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients

 

Bone

Lung

Liver

Brain

Costs in ɛ (NZA, 2014)

Reference

Sensitivity

Bone scintigraphy

80 (67–93)

NA

NA

NA

135

(Houssami and Costelloe, 2012)

X-ray

61 (57–66)

74 (67–80)

NA

NA

47

(Mahner et al, 2008, National Lung Screening Trial Research Team, 2013)

Magnetic resonance imaging

94 (92–96)

NA

81 (76–86)

96 (84–99)

251a/199b

(Weber et al, 2006; Costelloe et al, 2009; Floriani et al, 2010)

Ultrasound

NA

NA

63 (25–87)

NA

52

(Floriani et al, 2010)

Computed tomography

67 (48–80)

94 (91–96)

97 (89–100)

86 (71–93)

199

(Ellika et al, 2007; Mahner et al, 2008, National Lung Screening Trial Research Team, 2013, Sadigh et al, 2014)

FES-PETc

91 (88–100)

90 (82–97)

20 (10–30)

46 (40–52)

1.505

Expert opinion

FDG-PET

90 (88–96)

90 (88–96)

90 (88–96)

50 (40–60)

1.505

(Radan et al, 2006; Hahn et al, 2011;Evangelista et al, 2012; Murakami et al, 2012), Expert opinion

Specificity

Bone scintigraphy

86 (68–100)

NA

NA

NA

 

(Houssami and Costelloe, 2012)

X-ray

100 (99–100)

91 (91–92)

NA

NA

 

(Mahner et al, 2008, National Lung Screening Trial Research Team, 2013)

Magnetic resonance imaging

89 (76–100)

NA

97 (94–99)

62 (48–76)

 

(Weber et al, 2006; Costelloe et al, 2009; Floriani et al, 2010)

Ultrasound

NA

NA

98 (96–100)

NA

 

(Floriani et al, 2010)

Computed tomography

95 (80–95)

90 (90–100)

76 (68–84)

100 (92–100)

 

(Mahner et al, 2008, Hendriks et al, 2013; National Lung Screening Trial Research Team, 2013, Sadigh et al, 2014)

FES-PETc

99 (98–100)

99 (98–100)

99 (98–100)

99 (98–100)

 

Expert opinion

FDG-PET

81 (71–95)

81 (71–95)

81 (71–95)

50 (40–60)

 

(Hahn et al, 2011; Radan et al, 2006; Evangelista et al, 2012; Murakami et al, 2012), Expert opinion, Expert opinion

  1. Abbreviations: ER=oestrogen receptor; FDG=2-[18F]fluoro-2-deoxy-D-glucose; FES=16α-[18F]fluoro-17β-oestradiol; MRI=magnetic resonance imaging; NA=not applicable; PET=positron emission tomography.
  2. Listed are estimated averages (95% confidence interval).
  3. aPrice per bone MRI.
  4. bPrice per brain/liver MRI.
  5. cThe sensitivity and specificity values presented are relevant for ER-positive patients only.
Back to article page